If you are interested in learning more about this study, please call or email the contact person below
|Title||Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis|
|Description||Myasthenia gravis (MG) is a rare autoimmune disorder which causes the muscles to become weak because the immune system attacks the connection between the nerves and the muscles.
Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). An immunoglobin is a blood protein. Hizentra is being studied for the treatment of patients with MG. Hizentra is administered by an injection into the skin through a portable infusion pump, which may be easier for patients to administer than the current treatments.
Participants will be asked to complete 9 clinic visits and 3 telephone calls. It could take up to 30 weeks to complete all study visits.
Study visits will be at Erie County Medical Center
|Objective||The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).|
|Principal Investigator||SILVESTRI, NICHOLAS|
|Key Eligibility||ages 18 and older
|Disease Group||Autoimmune Disorders; Brain/Neurological Disorders|
|Treatment||Subcutaneous Immunoglobulin (SCIg)|